{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:35:03Z","timestamp":1793918103410,"version":"4.8.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Oxidative stress and persistent airway inflammation are thought to be important contributors to the development of chronic obstructive pulmonary disease (COPD). This review summarizes the evidence for targeting oxidative stress and inflammation in patients with COPD with mucolytic\/antioxidant thiols and inhaled corticosteroids (ICS), either alone or in combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main body<\/jats:title><jats:p>Oxidative stress is increased in COPD, particularly during acute exacerbations. It can be triggered by oxidant air pollutants and cigarette smoke and\/or by endogenous reactive oxygen species (ROS) released from mitochondria and activated inflammatory, immune and epithelial cells in the airways, together with a reduction in endogenous antioxidants such as glutathione (GSH). Oxidative stress also drives chronic inflammation and disease progression in the airways by activating intracellular signalling pathways and the release of further inflammatory mediators. ICS are anti-inflammatory agents currently recommended for use with long-acting bronchodilators to prevent exacerbations in patients with moderate-to-severe COPD, especially those with eosinophilic airway inflammation. However, corticosteroids can also increase oxidative stress, which may in turn reduce corticosteroid sensitivity in patients by several mechanisms. Thiol-based agents such as erdosteine, N-acetyl L-cysteine (NAC) and S-carboxymethylcysteine (S-CMC) are mucolytic agents that also act as antioxidants. These agents may reduce oxidative stress directly through the free sulfhydryl groups, serving as a source of reducing equivalents and indirectly though intracellular GSH replenishment. Few studies have compared the effects of corticosteroids and thiol agents on oxidative stress, but there is some evidence for greater antioxidant effects when they are administered together. The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) report supports treatment with antioxidants (erdosteine, NAC, S-CMC) in addition to standard-of-care therapy as they have been demonstrated to reduce COPD exacerbations. However, such studies have demonstrated that NAC and S-CMC reduced the exacerbation risk only in patients not treated with ICS, whereas erdosteine reduced COPD exacerbations irrespective of concomitant ICS use suggesting that erdosteine has additional pharmacological actions to ICS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Further clinical trials of antioxidant agents with and without ICS are needed to better understand the place of thiol-based drugs in the treatment of patients with COPD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12931-023-02500-8","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T02:01:43Z","timestamp":1690768903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD"],"prefix":"10.1186","volume":"24","author":[{"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome R.","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"9795","key":"2500_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(11)60988-4","volume":"378","author":"GG Brusselle","year":"2011","unstructured":"Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015\u201326.","journal-title":"Lancet"},{"issue":"1","key":"2500_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40169-015-0068-z","volume":"4","author":"PT King","year":"2015","unstructured":"King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015;4(1):68.","journal-title":"Clin Transl Med"},{"key":"2500_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","volume":"76","author":"B David","year":"2021","unstructured":"David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76:188\u201395.","journal-title":"Thorax"},{"key":"2500_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","volume":"204","author":"BR Celli","year":"2021","unstructured":"Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, Franssen FME, Humbert M, Hurst JR, O\u2019Donnell D, Pantoni L, Papi A, Rodriguez-Roisin R, Sethi S, Torres A, Vogelmeier CF, Wedzicha JA. An updated definition and severity classification of Chronic Obstructive Pulmonary Disease Exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204:1251\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"2500_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/thoraxjnl-2011-200768","volume":"67","author":"SD Aaron","year":"2012","unstructured":"Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238\u201343.","journal-title":"Thorax"},{"key":"2500_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/15412550802237531","volume":"5","author":"M Decramer","year":"2008","unstructured":"Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, Sethi S, Cooper CB. COPD as a lung disease with systemic consequences\u2014clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5:235\u201356.","journal-title":"COPD"},{"key":"2500_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/07853890.2012.732703","volume":"45","author":"W MacNee","year":"2013","unstructured":"MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med. 2013;45:291\u2013300.","journal-title":"Ann Med"},{"key":"2500_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1183\/09031936.06.00053805","volume":"28","author":"I Rahman","year":"2006","unstructured":"Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219\u201342.","journal-title":"Eur Respir J"},{"key":"2500_CR9","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.redox.2020.101544","volume":"33","author":"PJ Barnes","year":"2020","unstructured":"Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544.","journal-title":"Redox Biol"},{"key":"2500_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/B978-0-12-811908-2.00006-4","volume-title":"Coronary artery disease: from Biology to Clinical Practice","author":"S Tsalamandris","year":"2018","unstructured":"Tsalamandris S, VogiatziG, Antonopoulos AS, Tousoulis D. The role of oxidative stress. In: Tousoulis D, Editor, editors. Coronary artery disease: from Biology to Clinical Practice. London, UK: Elsevier Inc.; 2018. pp. 95\u2013100."},{"issue":"6809","key":"2500_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/35041687","volume":"408","author":"T Finkel","year":"2000","unstructured":"Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239\u201347.","journal-title":"Nature"},{"key":"2500_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050965","author":"PJ Barnes","year":"2022","unstructured":"Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants. 2022;11:965.","journal-title":"Antioxidants"},{"key":"2500_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.23736\/S0026-4806.22.07972-1","volume":"113","author":"F Nucera","year":"2022","unstructured":"Nucera F, Mumby S, Paudel KR, Dharwal V, DI Stefano A, Casolaro V, Hansbro PM, Adcock IM, Caramori G. Role of oxidative stress in the pathogenesis of COPD. Minerva Med. 2022;113:370\u2013404.","journal-title":"Minerva Med"},{"key":"2500_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/COPD.S42414","volume":"10","author":"BM Fischer","year":"2015","unstructured":"Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015;10:261\u201376.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2500_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1378\/chest.12-2664","volume":"144","author":"PA Kirkham","year":"2013","unstructured":"Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013;144:266\u201373.","journal-title":"Chest"},{"key":"2500_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2019.05.035","volume":"140","author":"K Ulrich","year":"2019","unstructured":"Ulrich K, Jakob U. The role of thiols in antioxidant systems. Free Radic Biol Med. 2019;140:14\u201327.","journal-title":"Free Radic Biol Med"},{"key":"2500_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1586\/17476348.2016.1121105","volume":"10","author":"MG Matera","year":"2016","unstructured":"Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10:89\u201397.","journal-title":"Expert Rev Respir Med"},{"key":"2500_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2019.04.015","volume":"40","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Thiol-based drugs in pulmonary medicine: much more than mucolytics. Trends Pharmacol Sci. 2019;40:452\u201363.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"2500_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/antiox6030062","volume":"6","author":"GJ McBean","year":"2017","unstructured":"McBean GJ. Cysteine, glutathione, and thiol redox balance in astrocytes. Antioxid (Basel). 2017;6(3):62.","journal-title":"Antioxid (Basel)"},{"issue":"2","key":"2500_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jaci.2015.01.023","volume":"136","author":"ST Stephenson","year":"2015","unstructured":"Stephenson ST, Brown LA, Helms MN, Qu H, Brown SD, Brown MR, Fitzpatrick AM. Cysteine oxidation impairs systemic glucocorticoid responsiveness in children with difficult-to-treat asthma. J Allergy Clin Immunol. 2015;136(2):454\u2013. \u2013 61.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"2500_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/bs.acc.2018.07.004","volume":"87","author":"G Teskey","year":"2018","unstructured":"Teskey G, Abrahem R, Cao R, Gyurjian K, Islamoglu H, Lucero M, Martinez A, Paredes E, Salaiz O, Robinson B, Venketaraman V. Glutathione as a marker for human disease. Adv Clin Chem. 2018;87:141\u201359.","journal-title":"Adv Clin Chem"},{"key":"2500_CR22","doi-asserted-by":"publisher","first-page":"9943","DOI":"10.1073\/pnas.87.24.9943","volume":"87","author":"FJ Staal","year":"1990","unstructured":"Staal FJ, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1990;87:9943\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2500_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/10715760500072149","volume":"39","author":"MJ Cuevas","year":"2005","unstructured":"Cuevas MJ, Almar M, Garc\u00eda-Glez JC, Garc\u00eda-L\u00f3pez D, De Paz JA, Alvear-Ordenes I, Gonz\u00e1lez-Gallego J. Changes in oxidative stress markers and NF-kappaB activation induced by sprint exercise. Free Radic Res. 2005;39:431\u20139.","journal-title":"Free Radic Res"},{"key":"2500_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/thx.2004.027946","volume":"60","author":"EM Drost","year":"2005","unstructured":"Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60:293\u2013300.","journal-title":"Thorax"},{"key":"2500_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.mam.2008.09.001","volume":"30","author":"A Fraternale","year":"2009","unstructured":"Fraternale A, Paoletti MF, Casabianca A, Nencioni L, Garaci E, Palamara AT, Magnani M. GSH and analogs in antiviral therapy. Mol Aspects Med. 2009;30:99\u2013110.","journal-title":"Mol Aspects Med"},{"key":"2500_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1183\/09031936.00213711","volume":"40","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40:724\u201341.","journal-title":"Eur Respir J"},{"key":"2500_CR27","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1517\/14656566.2013.848856","volume":"14","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14:2489\u201399.","journal-title":"Expert Opin Pharmacother"},{"key":"2500_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14656566.2022.2076592","volume":"23","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin Pharmacother. 2022;23:917\u201327.","journal-title":"Expert Opin Pharmacother"},{"key":"2500_CR29","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2023 GOLD Report. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2023. https:\/\/goldcopd.org\/2023-gold-report-2\/."},{"key":"2500_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bcp.12334","volume":"78","author":"KS Babu","year":"2014","unstructured":"Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol. 2014;78:282\u2013300.","journal-title":"Br J Clin Pharmacol"},{"key":"2500_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/COPD.S233462","volume":"15","author":"C Tantucci","year":"2020","unstructured":"Tantucci C, Pini L. Inhaled corticosteroids in COPD: trying to make a long story short. Int J Chron Obstruct Pulmon Dis. 2020;15:821\u201329.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2500_CR32","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2147\/COPD.S374670","volume":"17","author":"M Bafadhel","year":"2022","unstructured":"Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide\/Glycopyrronium\/Formoterol Fumarate Dihydrate on COPD Exacerbations, lung function, symptoms, and Quality of Life Across Blood Eosinophil ranges: a post-hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061\u201373.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2500_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","volume":"7","author":"S Pascoe","year":"2019","unstructured":"Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7:745\u201356.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2500_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, Schofield P, Armstrong D, White P. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3. https:\/\/doi.org\/10.1186\/s12931-019-1268-7.","journal-title":"Respir Res"},{"key":"2500_CR35","doi-asserted-by":"crossref","unstructured":"Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:F1000 Faculty Rev-1533.","DOI":"10.12688\/f1000research.19811.1"},{"key":"2500_CR36","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","volume":"74","author":"PJ Barnes","year":"2019","unstructured":"Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74:1249\u201356.","journal-title":"Allergy"},{"key":"2500_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","volume":"131","author":"PJ Barnes","year":"2013","unstructured":"Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636\u201345.","journal-title":"J Allergy Clin Immunol"},{"key":"2500_CR38","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa041892","volume":"352","author":"K Ito","year":"2005","unstructured":"Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967\u201376.","journal-title":"N Engl J Med"},{"issue":"9","key":"2500_CR39","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/antiox10091335","volume":"10","author":"BW Lewis","year":"2021","unstructured":"Lewis BW, Ford ML, Rogers LK, Britt RD Jr. Oxidative stress promotes corticosteroid insensitivity in asthma and COPD. Antioxid (Basel). 2021;10(9):1335. https:\/\/doi.org\/10.3390\/antiox10091335.","journal-title":"Antioxid (Basel)"},{"key":"2500_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/ph3030514","volume":"3","author":"PJ Barnes","year":"2010","unstructured":"Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3:514\u201340.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2500_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1378\/chest.08-0440","volume":"134","author":"IM Adcock","year":"2008","unstructured":"Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest. 2008;134:394\u2013401.","journal-title":"Chest"},{"key":"2500_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.intimp.2011.10.006","volume":"12","author":"J Plumb","year":"2012","unstructured":"Plumb J, Gaffey K, Kane B, Malia-Milanes B, Shah R, Bentley A, Ray D, Singh D. Reduced glucocorticoid receptor expression and function in airway neutrophils. Int Immunopharmacol. 2012;12:26\u201333.","journal-title":"Int Immunopharmacol"},{"key":"2500_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/thoraxjnl-2013-203520","volume":"69","author":"I Heijink","year":"2014","unstructured":"Heijink I, van Oosterhout A, Kliphuis N, Jonker M, Hoffmann R, Telenga E, Klooster K, Slebos DJ, ten Hacken N, Postma D, van den Berge M. Oxidant-induced corticosteroid unresponsiveness in human bronchial epithelial cells. Thorax. 2014;69:5\u201313.","journal-title":"Thorax"},{"key":"2500_CR44","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1096\/fj.12-222604","volume":"27","author":"A Hakim","year":"2013","unstructured":"Hakim A, Barnes PJ, Adcock IM, Usmani OS. Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB J. 2013;27:4510\u20139.","journal-title":"FASEB J"},{"key":"2500_CR45","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0024-3205(97)00193-8","volume":"60","author":"HJ Jos\u00e9","year":"1997","unstructured":"Jos\u00e9 HJ, Berenice SG, Cecilia VR. Induction of antioxidant enzymes by dexamethasone in the adult rat lung. Life Sci. 1997;60:2059\u201367.","journal-title":"Life Sci"},{"key":"2500_CR46","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0039-128X(02)00024-7","volume":"67","author":"BM Sanner","year":"2002","unstructured":"Sanner BM, Meder U, Zidek W, Tepel M. Effects of glucocorticoids on generation of reactive oxygen species in platelets. Steroids. 2002;67:715\u20139.","journal-title":"Steroids"},{"key":"2500_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.injr.2014.06.007","volume":"9","author":"MM Neha, Ansari","year":"2014","unstructured":"Neha, Ansari MM, Khan HA. Deflazacort alleviate pro-inflammatory cytokines expression, oxidative stress and histopathological alterations in collagen induced arthritis in Wistar rats. Indian J Rheumatol. 2014;9:167\u201377.","journal-title":"Indian J Rheumatol"},{"key":"2500_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1590\/S1806-37132014000300006","volume":"40","author":"RL Torres","year":"2014","unstructured":"Torres RL, Torres IL, Laste G, Ferreira MB, Cardoso PF, Bell\u00f3-Klein A. Effects of acute and chronic administration of methylprednisolone on oxidative stress in rat lungs. J Bras Pneumol. 2014;40:238\u201343.","journal-title":"J Bras Pneumol"},{"key":"2500_CR49","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3164\/jcbn.10-58","volume":"47","author":"H Sato","year":"2010","unstructured":"Sato H, Takahashi T, Sumitani K, Takatsu H, Urano S. Glucocorticoid generates ROS to induce oxidative injury in the hippocampus, leading to impairment of cognitive function of rats. J Clin Biochem Nutr. 2010;47:224\u201332.","journal-title":"J Clin Biochem Nutr"},{"key":"2500_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1755-5922.2010.00183.x","volume":"30","author":"R Maio","year":"2012","unstructured":"Maio R, Perticone M, Sciacqua A, Tassone EJ, Naccarato P, Bagnato C, Iannopollo G, Sesti G, Perticone F. Oxidative stress impairs endothelial function in nondipper hypertensive patients. Cardiovasc Ther. 2012;30:85\u201392.","journal-title":"Cardiovasc Ther"},{"key":"2500_CR51","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1210\/en.2009-0195","volume":"150","author":"S Qiao","year":"2009","unstructured":"Qiao S, Okret S, Jondal M. Thymocyte-synthesized glucocorticoids play a role in thymocyte homeostasis and are down-regulated by adrenocorticotropic hormone. Endocrinology. 2009;150:4163\u20139.","journal-title":"Endocrinology"},{"key":"2500_CR52","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1593\/neo.101146","volume":"12","author":"S Bera","year":"2010","unstructured":"Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ, Goel A. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia. 2010;12:980\u201392.","journal-title":"Neoplasia"},{"key":"2500_CR53","first-page":"447","volume":"181","author":"D Costantini","year":"2011","unstructured":"Costantini D, Marasco V, M\u00f8ller AP. A meta-analysis of glucocorticoids as modulators of oxidative stress in vertebrates. J Comp Physiol B. 2011;181:447\u201356.","journal-title":"J Comp Physiol B"},{"key":"2500_CR54","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s40265-020-01412-x","volume":"80","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG. Multifaceted beneficial effects of erdosteiXXXoreore than a mucolytic agent. Drugs. 2020;80:1799\u2013809.","journal-title":"Drugs"},{"key":"2500_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11010-006-0640-3","volume":"281","author":"H Boyaci","year":"2006","unstructured":"Boyaci H, Maral H, Turan G, Ba\u015fyi\u011fit I, Dillio\u011flugil MO, Yildiz F, Tugay M, Pala A, Er\u00e7in C. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem. 2006;281:129\u201337.","journal-title":"Mol Cell Biochem"},{"key":"2500_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jat.1133","volume":"26","author":"R Demiralay","year":"2006","unstructured":"Demiralay R, G\u00fcrsan N, Ozbilim G, Erdogan G, Demirci E. Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury. J Appl Toxicol. 2006;26:301\u20138.","journal-title":"J Appl Toxicol"},{"key":"2500_CR57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jss.2017.02.061","volume":"213","author":"A Erdem","year":"2017","unstructured":"Erdem A, Gedikli E, Yersal N, Karaismailoglu S, Muftuoglu S, Fadillioglu E, Tuncer M. Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury. J Surg Res. 2017;213:234\u201342.","journal-title":"J Surg Res"},{"key":"2500_CR58","first-page":"367","volume":"18","author":"T Kurtoglu","year":"2007","unstructured":"Kurtoglu T, Sacar M, Inan BK, Duver MH, Guler A, Ucak A, Us MH, Yilmaz AT. Erdosteine ameliorates lung injury induced by transient aortic occlusion in rats. Cardiovasc J Afr. 2007;18:367\u201370.","journal-title":"Cardiovasc J Afr"},{"key":"2500_CR59","doi-asserted-by":"crossref","unstructured":"Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res. 2007;55,249 \u2013 54.","DOI":"10.1016\/j.phrs.2006.12.006"},{"key":"2500_CR60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/01480545.2019.1659810","volume":"45","author":"M Dobrakowski","year":"2022","unstructured":"Dobrakowski M, Macho\u0144-Grecka A, Nowak P, Szcz\u0119sny P, Maciejczyk M, Kasperczyk A, Pryzwan T, Kasperczyk S. The influence of erdosteine administration on lead-induced oxidative stress in rat muscle. Drug Chem Toxicol. 2022;45:88\u201392.","journal-title":"Drug Chem Toxicol"},{"key":"2500_CR61","first-page":"700","volume":"61","author":"L Marabini","year":"2011","unstructured":"Marabini L, Cal\u00f2 R, Braga PC. Protective effect of erdosteine metabolite I against hydrogen peroxide-induced oxidative DNA-damage in lung epithelial cells. Arzneimittelforschung. 2011;61:700\u20136.","journal-title":"Arzneimittelforschung"},{"key":"2500_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pupt.2018.10.005","volume":"53","author":"R Dal Negro","year":"2018","unstructured":"Dal Negro R, Pozzi E, Cella SG, Erdosteine. Drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulm Pharmacol Ther. 2018;53:80\u20135.","journal-title":"Pulm Pharmacol Ther"},{"key":"2500_CR63","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.pupt.2007.07.004","volume":"21","author":"RW Dal Negro","year":"2008","unstructured":"Dal Negro RW, Visconti M, Micheletto C, Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;21:304\u20138.","journal-title":"Pulm Pharmacol Ther"},{"key":"2500_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1753465808096109","volume":"2","author":"R Dal Negro","year":"2008","unstructured":"Dal Negro R, Visconti M, Trevisan F, Bertacco S, Micheletto C, Tognella S. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Ther Adv Respir Dis. 2008;2:271\u20137.","journal-title":"Ther Adv Respir Dis"},{"key":"2500_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pupt.2015.06.004","volume":"33","author":"RW Dal Negro","year":"2015","unstructured":"Dal Negro RW, Visconti M, Turco P. Efficacy of erdosteine 900 versus 600\u00a0mg\/day in reducing oxidative stress in patients with COPD exacerbations: results of a double blind, placebo-controlled trial. Pulm Pharmacol Ther. 2015;33:47\u201351.","journal-title":"Pulm Pharmacol Ther"},{"key":"2500_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pupt.2016.09.007","volume":"41","author":"RW Dal Negro","year":"2016","unstructured":"Dal Negro RW, Visconti M. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: results of a placebo-controlled trial. Pulm Pharmacol Ther. 2016;41:48\u201351.","journal-title":"Pulm Pharmacol Ther"},{"key":"2500_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17476348.2018.1495562","volume":"12","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018;12:693\u2013708.","journal-title":"Expert Rev Respir Med"},{"key":"2500_CR68","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.chembiol.2018.01.011","volume":"25","author":"D Ezeri\u0146a","year":"2018","unstructured":"Ezeri\u0146a D, Takano Y, Hanaoka K, Urano Y, Dick TP. N-Acetyl -cysteine functions as a fast-acting antioxidant by triggering intracellular H2S and sulfane sulfur production. Cell Chem Biol. 2018;25:447\u201359.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2500_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12931-016-0500-y","volume":"18","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017;18(1):26.","journal-title":"Respir Res"},{"key":"2500_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.04.011","volume":"103","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018;103:1\u20138.","journal-title":"Biomed Pharmacother"},{"key":"2500_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/thx.46.1.39","volume":"46","author":"MM Bridgeman","year":"1991","unstructured":"Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax. 1991;46:39\u201342.","journal-title":"Thorax"},{"issue":"6","key":"2500_CR72","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/pharmaceutics14061261","volume":"14","author":"E Pace","year":"2022","unstructured":"Pace E, Cerveri I, Lacedonia D, Paone G, Sanduzzi Zamparelli A, Sorbo R, Allegretti M, Lanata L, Scaglione F. Clinical efficacy of carbocysteine in COPD: beyond the mucolytic action. Pharmaceutics. 2022;14(6):1261.","journal-title":"Pharmaceutics"},{"key":"2500_CR73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1440-1843.2008.01424.x","volume":"14","author":"H Nogawa","year":"2009","unstructured":"Nogawa H, Ishibashi Y, Ogawa A, Masuda K, Tsubuki T, Kameda T, Matsuzawa S. Carbocisteine can scavenge reactive oxygen species in vitro. Respirology. 2009;14:53\u20139.","journal-title":"Respirology"},{"key":"2500_CR74","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000185494","volume":"22","author":"ML Garavaglia","year":"2008","unstructured":"Garavaglia ML, Bononi E, Dossena S, Mondini A, Bazzini C, Lanata L, Balsamo R, Bagnasco M, Conese M, Bott\u00e0 G, Paulmichl M, Meyer G. S-CMC-Lys protective effects on human respiratory cells during oxidative stress. Cell Physiol Biochem. 2008;22:455\u201364.","journal-title":"Cell Physiol Biochem"},{"key":"2500_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejphar.2004.10.007","volume":"505","author":"GE Carpagnano","year":"2004","unstructured":"Carpagnano GE, Resta O, Foschino-Barbaro MP, Spanevello A, Stefano A, Di Gioia G, Serviddio G, Gramiccioni E. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol. 2004;505:169\u201375.","journal-title":"Eur J Pharmacol"},{"key":"2500_CR76","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s000110050447","volume":"48","author":"K Miyake","year":"1999","unstructured":"Miyake K, Kaise T, Hosoe H, Akuta K, Manabe H, Ohmori K. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflamm Res. 1999;48:205\u20139.","journal-title":"Inflamm Res"},{"key":"2500_CR77","unstructured":"Mitrea M, Silvestro L, Savu S, Mancini C. Reduced (GSH) and oxidized (GSSG) levels in plasma and BAL of chronic bronchitis patients treated with erdosteine or N-acetylcysteine (NAC). Abstract presented at the 6th International Conference on Bronchoalveolar Lavage, Corfu, Greece; 1998, 24\u201327 June."},{"key":"2500_CR78","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12192-013-0424-0","volume":"18","author":"E Pace","year":"2013","unstructured":"Pace E, Ferraro M, Di Vincenzo S, Cipollina C, Gerbino S, Cigna D, Caputo V, Balsamo R, Lanata L, Gjomarkaj M. Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells. Cell Stress Chaperones. 2013;18:733\u201343.","journal-title":"Cell Stress Chaperones"},{"key":"2500_CR79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-2249.2000.01373.x","volume":"122","author":"D Rocks\u00e9n","year":"2000","unstructured":"Rocks\u00e9n D, Lillieh\u00f6\u00f6k B, Larsson R, Johansson T, Bucht A. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol. 2000;122:249\u201356.","journal-title":"Clin Exp Immunol"},{"key":"2500_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.tox.2014.12.008","volume":"328","author":"E Wigenstam","year":"2015","unstructured":"Wigenstam E, Koch B, Bucht A, Jonasson S. N-acetyl cysteine improves the effects of corticosteroids in a mouse model of chlorine-induced acute lung injury. Toxicology. 2015;328:40\u20137.","journal-title":"Toxicology"},{"key":"2500_CR81","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.injury.2008.05.001","volume":"40","author":"H T\u00fcr\u00fct","year":"2009","unstructured":"T\u00fcr\u00fct H, Ciralik H, Kilinc M, Ozbag D, Imrek SS. Effects of early administration of dexamethasone, N-acetylcysteine and aprotinin on inflammatory and oxidant-antioxidant status after lung contusion in rats. Injury. 2009;40:521\u20137.","journal-title":"Injury"},{"key":"2500_CR82","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s12325-008-0064-4","volume":"25","author":"S Kuleci","year":"2008","unstructured":"Kuleci S, Hanta I, Kocabas A, Canacankatan N. The effect of different treatment modalities on oxidative stress in COPD. Adv Ther. 2008;25:710\u20137.","journal-title":"Adv Ther"},{"issue":"Suppl 4","key":"2500_CR83","first-page":"135","volume":"56","author":"FJ van Overveld","year":"2005","unstructured":"van Overveld FJ, Demkow U, G\u00f3recka D, de Backer WA, Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol. 2005;56(Suppl 4):135\u201342.","journal-title":"J Physiol Pharmacol"},{"key":"2500_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000084295","volume":"74","author":"M Dal Sasso","year":"2005","unstructured":"Dal Sasso M, Culici M, Guffanti EE, Bianchi T, Fonti E, Braga PC. A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology. 2005;74:127\u201334.","journal-title":"Pharmacology"},{"key":"2500_CR85","first-page":"184","volume":"12","author":"P Eftekhari","year":"2013","unstructured":"Eftekhari P, Hajizadeh S, Raoufy MR, Masjedi MR, Yang M, Hansbro N, Li JJ, Foster PS. Preventive effect of N-acetylcysteine in a mouse model of steroid resistant acute exacerbation of asthma. EXCLI J. 2013;12:184\u201392.","journal-title":"EXCLI J"},{"key":"2500_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cbi.2013.11.004","volume":"207","author":"YL Feng","year":"2014","unstructured":"Feng YL, Tang XL. Effect of glucocorticoid-induced oxidative stress on the expression of Cbfa1. Chem Biol Interact. 2014;207:26\u201331.","journal-title":"Chem Biol Interact"},{"key":"2500_CR87","first-page":"3911","volume":"38","author":"V Kapustina","year":"2011","unstructured":"Kapustina V, Ovcharenko S, Litvicki P. High doses of N-acetylcysteine alone or in combination with inhaled corticosteroids and oxidative stress in patients with COPD [abstract]. Eur Respir J. 2011;38:3911.","journal-title":"Eur Respir J"},{"key":"2500_CR88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2014.12.002","volume":"91","author":"Y Song","year":"2015","unstructured":"Song Y, Lu HZ, Xu JR, Wang XL, Zhou W, Hou LN, Zhu L, Yu ZH, Chen HZ, Cui YY. Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol\/GSH-dependent manner. Pharmacol Res. 2015;91:88\u201398.","journal-title":"Pharmacol Res"},{"key":"2500_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pupt.2016.06.003","volume":"39","author":"Y Song","year":"2016","unstructured":"Song Y, Yu P, Lu JJ, Lu HZ, Zhu L, Yu ZH, Chen HZ, Cui YY. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model. Pulm Pharmacol Ther. 2016;39:38\u201347.","journal-title":"Pulm Pharmacol Ther"},{"key":"2500_CR90","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1002\/jcp.25710","volume":"232","author":"E Pace","year":"2017","unstructured":"Pace E, Di Vincenzo S, Ferraro M, Siena L, Chiappara G, Dino P, Vitulo P, Bertani A, Saibene F, Lanata L, Gjomarkaj M. Effects of carbocysteine and beclomethasone on histone acetylation\/deacetylation processes in cigarette smoke exposed bronchial epithelial cells. J Cell Physiol. 2017;232:2851\u20139.","journal-title":"J Cell Physiol"},{"key":"2500_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12931-017-0682-y","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Cos\u00edo BG, Arnedillo A, Calle M, Alc\u00e1zar-Navarrete B, Gonz\u00e1lez C, Esteban C, Trigueros JA, Rodr\u00edguez Gonz\u00e1lez-Moro JM, Quintano Jim\u00e9nez JA, Baloira A. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res. 2017;18:198.","journal-title":"Respir Res"},{"key":"2500_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41533-023-00334-x","volume":"33","author":"J Kocks","year":"2023","unstructured":"Kocks J, Ferreira AJ, Bakke P, van Schayck OCP, Ekroos H, Tzanakis N, Soulard S, Haaksma-Herczegh M, Mestres-Simon M, \u00c1guila-Fuentes M, Cataldo D. Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study. NPJ Prim Care Respir Med. 2023;33:18.","journal-title":"NPJ Prim Care Respir Med"},{"key":"2500_CR93","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS. PANTHEON study group. Twice daily N-acetylcysteine 600\u00a0mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187\u201394.","journal-title":"Lancet Respir Med"},{"issue":"9629","key":"2500_CR94","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","volume":"371","author":"JP Zheng","year":"2008","unstructured":"Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet. 2008;371(9629):2013\u20138.","journal-title":"Lancet"},{"issue":"4","key":"2500_CR95","doi-asserted-by":"publisher","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","volume":"50","author":"RW Dal Negro","year":"2017","unstructured":"Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50(4):1700711.","journal-title":"Eur Respir J"},{"key":"2500_CR96","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.rce.2019.04.007","volume":"219","author":"WA Sep\u00falveda Loyola","year":"2019","unstructured":"Sep\u00falveda Loyola WA, Vila\u00e7a Cavallari Machado F, Ara\u00fajo de Castro L, Hissnauer Leal Baltus T, Rampazzo Morelli N, Landucci Bonif\u00e1cio K, Morita AA, Michelin AP, Sabbatini Barbosa D, Probst VS. Is oxidative stress associated with disease severity, pulmonary function and metabolic syndrome in chronic obstructive pulmonary disease? Rev Clin Esp. 2019;219:477\u201384.","journal-title":"Rev Clin Esp"},{"key":"2500_CR97","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0954-6111(98)90225-6","volume":"92","author":"CP van Schayck","year":"1998","unstructured":"van Schayck CP, Dekhuijzen PN, Gorgels WJ, van Grunsven PM, Molema J, van Herwaarden CL, van Weel C. Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. Respir Med. 1998;92:1259\u201364.","journal-title":"Respir Med"},{"key":"2500_CR98","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2019 GOLD Report. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf."},{"issue":"9470","key":"2500_CR99","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","volume":"365","author":"M Decramer","year":"2005","unstructured":"Decramer M, Rutten-van M\u00f6lken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552\u201360.","journal-title":"Lancet"},{"key":"2500_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.rmed.2018.12.014","volume":"147","author":"A Papi","year":"2019","unstructured":"Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study. Respir Med. 2019;147:37\u201343.","journal-title":"Respir Med"},{"key":"2500_CR101","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/COPD.S221852","volume":"14","author":"PM Calverley","year":"2019","unstructured":"Calverley PM, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019;14:2733\u201344.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"2500_CR102","first-page":"CD001287","volume":"5","author":"P Poole","year":"2019","unstructured":"Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2500_CR103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12931-019-1078-y","volume":"20","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104.","journal-title":"Respir Res"},{"key":"2500_CR104","first-page":"799","volume":"11","author":"K Johnson","year":"2016","unstructured":"Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, Wetherbee EE, Nelson D, Tirouvanziam R, Niewoehner DE. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016;11:799\u2013807.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2500_CR105","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5507\/bp.2020.056","volume":"164","author":"J Zatloukal","year":"2020","unstructured":"Zatloukal J, Brat K, Neumannova K, Volakova E, Hejduk K, Kocova E, Kudela O, Kopecky M, Plutinsky M, Koblizek V. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(4):325\u201356.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"2500_CR106","doi-asserted-by":"publisher","first-page":"106190","DOI":"10.1016\/j.rmed.2020.106190","volume":"175","author":"A Papi","year":"2020","unstructured":"Papi A, Avdeev S, Calverley PMA, Cordeiro CR, Jesenak M, Kobl\u00ed\u017eek V, Petkova D, Rogliani P, Tarraf H, Tzanakis N, Ulmeanu R, Uzaslan E, Adir Y. Use of mucolytics in COPD: a Delphi consensus study. Respir Med. 2020;175:106190.","journal-title":"Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02500-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T03:29:28Z","timestamp":1702870168000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02500-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2500"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02500-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC, CPP, JAW, BRC, and AA report personal fees from Edmond Pharma. The authors report no other conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}